R-sibutramine metabolite - Sepracor

Drug Profile

R-sibutramine metabolite - Sepracor

Alternative Names: (+)-Desmethylsibutramine - Sepracor; (+)-Didesmethylsibutramine - Sepracor; R-DDMS; R-Desmethylsibutramine - Sepracor; R-Didesmethylsibutramine - Sepracor

Latest Information Update: 27 Jun 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sepracor
  • Class
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder; Erectile dysfunction; Major depressive disorder; Stress incontinence

Most Recent Events

  • 27 Jun 2006 No development reported - Phase-I for Attention-deficit hyperactivity disorder in USA (PO)
  • 27 Jun 2006 No development reported - Phase-I for Stress incontinence in USA (unspecified route)
  • 27 Jun 2006 No development reported - Phase-II for Depression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top